Clover Biopharmaceuticals, Ltd.
HKEX:2197.HK
0.98 (HKD) • At close September 1, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) HKD.
| 2024 Q4 | 2024 Q2 | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 48.519 | -10.1 | 38.998 | 0.257 | 0 | 14.884 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 711.204 | 0.158 | 475.514 | 1,236.906 | 483.085 | 7.442 | 66.267 | 0 | 0 | 0 | 0 | 0 |
| Brutowinst
| -662.685 | -10.258 | -436.516 | -1,236.649 | -483.085 | 7.442 | -66.267 | 0 | 0 | 0 | 0 | 0 |
| Brutowinstmarge
| -13.658 | 1.016 | -11.193 | -4,811.864 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 85.09 | 98.297 | 264.282 | 385.603 | 610.059 | 855.265 | 1,192.46 | 633.841 | 114.11 | 114.11 | 22.9 | 22.9 |
| Algemene en administratieve kosten
| 33.097 | 42.075 | 89.348 | 109.468 | 184.894 | 225.343 | 220.908 | 124.802 | 38.215 | 38.215 | 8.518 | 8.518 |
| Verkoop- en marketingkosten
| 13.021 | 6.684 | 32.255 | 22.511 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 46.118 | 48.759 | 121.603 | 131.979 | 184.894 | 225.343 | 220.908 | 124.802 | 38.215 | 38.215 | 8.518 | 8.518 |
| Overige kosten
| 0 | 0 | 0 | -2,797.761 | -990.33 | 0 | 0 | 0 | -10.18 | -10.18 | -7.955 | -7.955 |
| Bedrijfskosten
| 131.208 | 147.056 | 385.885 | 1,889.204 | 832.836 | 1,146.001 | 4,641.742 | 1,310.968 | 142.145 | 142.145 | 23.463 | 23.463 |
| Bedrijfsresultaat
| -793.893 | -157.314 | -822.401 | -1,760.486 | -1,291.529 | -1,108.685 | -1,480.034 | -758.677 | -454.963 | -454.963 | -19.126 | -19.126 |
| Bedrijfsresultaat ratio
| -16.363 | 15.576 | -21.088 | -6,850.14 | 0 | -74.488 | 0 | 0 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| -14.412 | 62.191 | 33.238 | 2,411.11 | -24.289 | -48.035 | -3,221.918 | -556.073 | -304.125 | -304.125 | -5.166 | -5.166 |
| Inkomen voor belasting
| -808.305 | -95.123 | -789.163 | 650.624 | -1,315.818 | -1,136.085 | -4,701.553 | -1,314.75 | -456.449 | -456.449 | -24.292 | -24.292 |
| Inkomen voor belasting ratio
| -16.66 | 9.418 | -20.236 | 2,531.611 | 0 | -76.329 | 0 | 0 | 0 | 0 | 0 | 0 |
| Belastingkosten
| 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 1.487 | 1.487 | 5.166 | 5.166 |
| Nettowinst
| -808.305 | -95.123 | -789.163 | 650.624 | -1,315.818 | -1,136.085 | -4,701.553 | -1,314.75 | -457.936 | -457.936 | -29.458 | -29.458 |
| Nettowinstmarge
| -16.66 | 9.418 | -20.236 | 2,531.611 | 0 | -76.329 | 0 | 0 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -0.64 | -0.08 | -0.64 | 0.52 | -1.18 | -1.06 | -4.06 | -1.136 | -0.39 | -0.39 | -0.025 | -0.025 |
| Verwaterde WPA
| -0.64 | -0.076 | -0.64 | 0.52 | -1.18 | -1.04 | -4.06 | -1.136 | -0.39 | -0.39 | -0.025 | -0.025 |
| EBITDA
| -777.118 | -139.422 | -819.739 | -1,743.179 | -1,276.71 | -1,094.524 | -1,471.771 | -754.646 | -167.521 | -167.521 | -30.881 | -30.881 |
| EBITDA ratio
| -16.017 | 13.804 | -21.02 | -6,782.798 | 0 | -73.537 | 0 | 0 | 0 | 0 | 0 | 0 |